NEW YORK (GenomeWeb News) – Bio-Rad Laboratories has purchased next-generation sequencing technology firm GnuBio for an undisclosed price in order to give it capabilities in the NGS space, especially for clinical applications, Bio-Rad said this week.

Cambridge, Mass.-based GnuBio is developing a droplet-based sequencing platform that uses "picoinjector" technology developed in co-founder David Weitz’s physics laboratory at Harvard University.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.